Nanexa (40M) Stock Overview
A pharmaceutical company, develops injectable drug products in the Nordic countries, rest of Europe, and North America. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
40M Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Nanexa AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.18 |
| 52 Week High | SEK 0.24 |
| 52 Week Low | SEK 0.055 |
| Beta | 1.87 |
| 1 Month Change | -17.85% |
| 3 Month Change | 80.68% |
| 1 Year Change | 163.96% |
| 3 Year Change | -12.10% |
| 5 Year Change | n/a |
| Change since IPO | -83.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| 40M | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 3.7% | -1.2% | -0.3% |
| 1Y | 164.0% | -12.2% | 16.9% |
Return vs Industry: 40M exceeded the German Medical Equipment industry which returned -12.6% over the past year.
Return vs Market: 40M exceeded the German Market which returned 18.3% over the past year.
Price Volatility
| 40M volatility | |
|---|---|
| 40M Average Weekly Movement | 18.6% |
| Medical Equipment Industry Average Movement | 6.3% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 40M's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 40M's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 13 | David Westberg | nanexa.com |
Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, rest of Europe, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a depot drug from azacitidine to treat myelodysplastic syndrome; and NEX-20, a depot drug from lenalidomide for the treatment of multiple myeloma.
Nanexa AB (publ) Fundamentals Summary
| 40M fundamental statistics | |
|---|---|
| Market cap | €32.71m |
| Earnings (TTM) | -€2.78m |
| Revenue (TTM) | €3.61m |
Is 40M overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 40M income statement (TTM) | |
|---|---|
| Revenue | SEK 40.31m |
| Cost of Revenue | SEK 15.42m |
| Gross Profit | SEK 24.88m |
| Other Expenses | SEK 55.95m |
| Earnings | -SEK 31.07m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 27, 2025
| Earnings per share (EPS) | -0.20 |
| Gross Margin | 61.73% |
| Net Profit Margin | -77.08% |
| Debt/Equity Ratio | 23.2% |
How did 40M perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/22 12:28 |
| End of Day Share Price | 2025/07/22 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nanexa AB (publ) is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gonzalo Artiach Castanon | ABG Sundal Collier Sponsored |
| Fredrik Thor | Redeye |